Baloxavir acid|S-033447|CAS 1985605-59-1|DC Chemicals

Cas No.:	1985605-59-1
Chemical Name:	(R)-12-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione
Synonyms:	Baloxavir; Baloxavir acid; BXA
SMILES:	N12C=CC(=O)C(O)=C1C(=O)N1CCOC[C@]1([H])N2[C@@H]1C2=CC=C(F)C(F)=C2CSC2=CC=CC=C21
Formula:	C₂₄H₁₉F₂N₃O₄S
M.Wt:	483.49
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Baloxavir is an anti-influenza agent extracted from patent WO 2017104691 A1.
Target:	Influenza virus[1]
References:	[1]. Shishido Takao, et al. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug. WO 2017104691 A1.

Cat. No.	Product name	Field of application
DC76071	VV261	VV261 is an orally active Influenza Virus inhibitor. VV261 has demonstrated activity against severe febrile thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus (LCMV) (EC50: 0.89 and 0.15, respectively).
DC72995	ING-1466	ING-1466 is an orally active entry inhibitor of influenza A viruses (IAVs) with EC50 of 0.18 uM against IAV H1N1 (PR8-NS1-Gluc), binds to hemagglutinin (HA) and blocks HA-mediated viral infection.
DC11030	S119-8	S119-8 is a novel broad spectrum inhibitor of influenza virus replication (IC50=1.43 nM) by targeting the viral Nucleoprotein (NP), with no detectable cytotoxicity (CC50>50 uM).
DC9486	Nucleozin	Nucleozin targets influenza A nucleoprotein (NP), a multifunctional, RNA-binding protein necessary for virus replication.
DC1108	Laninamivir (CS-8958)	Laninamivir (CS-8958) is a neuraminidase inhibitor which is being researched for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B.
DC11057	Baloxavir acid	Baloxavir acid (S-033447) is an anti-influenza compound that potently and selectively inhibits the cap-dependent endonuclease within the polymerase PA subunit of influenza A and B viruses.